Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Jnj-17166864 Cation. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jnj-17166864 Cation SCHEMBL2739842 | 0.99 | CCR2 (1.00) | CCR2CCR5 | |
| Jnj-17166864 Cation SCHEMBL29395095 | 0.99 | CCR2 (1.00) | CCR2CCR5 | |
| Jnj-17166864 Cation SCHEMBL313761 | 0.98 | CCR2 (0.98) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL2905790 | 0.92 | CCR2 (0.83) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL2908031 | 0.91 | CCR2 (0.98) | CCR2CCR5 | |
| SCHEMBL13148156 | 0.91 | CCR2 (0.85) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL313168 | 0.91 | CCR2 (0.81) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL312908 | 0.90 | CCR2 (0.98) | CCR2CCR5 | |
| Iodide SCHEMBL17555131 | 0.90 | CCR2 (0.83) | CCR2CCR5 | |
| SCHEMBL13148151 | 0.90 | CCR2 (1.00) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579309-B2 | Prophylactic or therapeutic agent for posterior ocular disease containing tetrahydropyranylaminocyclopentylcarbonyltetrahydropyridopyridine derivative as effective ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-20160008333-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR OCULAR DISEASE CONTAINING TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS EFFECTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-01-14 | — | — | US | disclosed |
| US-8168829-B2 | Synthesis of quaternary salt compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-01 | — | — | US | disclosed |
| US-8093428-B2 | Synthesis of quaternary salt compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-10 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2220041-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-25 | — | — | EP | disclosed |
| EP-2212286-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090112004-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009055519-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055516-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
| EP-1765803-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-28 | — | — | EP | disclosed |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | KENVUE BRANDS LLC | 2006-12-28 | — | — | US | disclosed |
| WO-2006012135-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | CCR2, CCR1, CCL11 | CCR2 1/4885CCR5 7/4885 |
| US-20090112004-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | CCR2, CCR1, CCL11 | CCR2 1/4885CCR5 7/4885 |
| US-20160008333-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR OCULAR DISEASE CONTAINING TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS EFFECTIVE INGREDIENT | UACA, ALDH1A2, PPHLN1 | CCR2 3416/4885CCR5 2052/4885 |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | CCR2, CCR1, CXCR2 | CCR2 1/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.